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Background: Physicians attempt to achieve glycemic goals in patients with type 2 diabetes 
mellitus (T2DM) through various means, including glucose-lowering medications. There is 
interindividual variability in response to medications, which can be partially explained by the 
presence of genetic polymorphisms that affect drug metabolism. Pharmacogenomics studies 
the hereditary basis of interpatient variations in drug response and aims to identify subgroups 
of patients whose drug management could be tailored accordingly. The aim of this review is 
to explore patient profiling in the management of T2DM with a focus on the sodium glucose 
transporter inhibitor canagliflozin.
Methods: The PubMed database was searched using the terms “pharmacogenomics” and 
“diabetes” through May 31, 2014. Published articles and abstracts presented at national/
international meetings were considered.
Results and conclusion: Genome-wide association studies have opened the door for patient 
profiling and research into genetic variants in multifactorial T2DM. Clinically, it may be 
possible to tailor the type of medication used based on the presence or absence of the various 
genetic variants. However, the polymorphisms studied may only explain some of the variability 
in response to T2DM drugs and needs further validation to ensure its authenticity. There are 
still unidentified factors which appear to play a role in the interindividual variability seen in 
clinical practice. The potential exists for pharmacogenomics to promote efficacious, safe, and 
cost-effective individualized diabetes management. Pharmacogenomics is still in its early stages, 
and the idea of defining patients genetically to predict individual responses to drugs and obtain 
safe and effective T2DM management is promising, in spite of existing barriers. Currently, 
clinical profiling of patients with T2DM and using an individualized approach with most drugs, 
including canagliflozin, based on comorbid conditions still remains the most accepted approach 
for the management of T2DM.
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Introduction
The primary goal of type 2 diabetes mellitus (T2DM) management is to prevent long-
term complication. Even with various means, including glucose-lowering medications, 
there are still barriers to achieving and maintaining glycemic goals.1 In the 2012 
position statement, the American Diabetes Association emphasized that individual-
izing the management with consideration to different clinical factors is important.2 
However, it is difficult for the guidelines to take into account individual variation in 
responses to pharmacological and lifestyle interventions. Physicians attempt to achieve 
glycemic goals through an algorithmic approach based on the patient’s responses to 
various antihyperglycemic agents. The wide interpatient variability seen in clinical Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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practice can be partially explained by the presence of genetic 
polymorphisms which affect the absorption, distribution, 
metabolism, and excretion of drugs.
Pharmacogenomics studies the hereditary basis of 
interpatient variations in drug response and aims to identify 
subgroups of patients whose drug management could be 
tailored accordingly. This can be an important step in true 
individualization of therapy, which is lacking at present. 
The aim of this review is to explore patient profiling in the 
management of T2DM with a focus on the sodium glucose 
transporter inhibitor canagliflozin.
Genetic variants associated with 
response to oral antihyperglycemic 
agents metformin
The American Diabetes Association recommends metformin 
as the first line drug to be used in patients with T2DM.3 
Response to metformin can vary significantly at the indi-
vidual level and cannot be predicted by any features found 
clinically.4 In fact, in 2,064 T2DM patients, the glycemic 
response to metformin was similar in nonobese and obese 
patients.4 Metformin is hydrophilic and needs active trans-
portation into the tissues.5 The main transporters are the 
PMAT encoded by the gene SLC29A4, OCT1 encoded by 
gene SLC22A1, OCT2 encoded by gene SLC22A2 and OCT3 
encoded by gene SLC22A3.6–8 In the renal cell, there are two 
other transporters called MATE1 and MATE2 encoded by 
genes SLC47A1 and SLC47A2, respectively.8
In a retrospective study in 24 responders and nine 
nonresponders of metformin in T2DM patients, the single 
nucleotide polymorphisms (SNPs) of SLC22A1, -43T.G 
in intron 1, was a negative predictor of metformin response 
while the variant 408 Met .Val (1222A.G) in exon 7 
was a positive predictor, with a predictive accuracy of 
55.5% (P,0.05).9 In the Rotterdam study, with 102 T2DM 
patients, where associations between eleven SNPs in the 
SLC22A1 gene and change in the A1c were analyzed, the SNP 
rs622342 was associated with the glucose-lowering effect 
of metformin.7 For each minor C allele at rs622342, the A1c 
levels were reduced by 0.28% (95% confidence interval [CI] 
0.09–0.47, P=0.005).7
A genome-wide association study on glycemic response 
to metformin in 1,024 Scottish patients with T2DM was 
done, and replication was attempted in two cohorts of 
1,783 Scottish patients and 1,113 patients from the United 
Kingdom Prospective Diabetes Study (UKPDS).10
In 1,024 Scottish observational genetic cohort on met-
formin therapy, the minor C allele of the most strongly 
associated SNP, rs11212617, had a frequency of 44% and was 
associated with treatment success (A1c ,7%), with an allelic 
odds ratio (OR) of 1.64 (95% CI 1.37–1.99, P=1.9×10-7), 
and it was associated with lower treatment A1c (per allele 
β -0.18% [95% CI -0.26 to -0.1], P=1.8×10-5). In the two 
replication cohorts, the minor C allele of rs11212617 was 
associated with treatment success: allelic OR 1.21, 95% CI 
1.05–1.38, P=0.007 and allelic OR 1.37, 95% CI 1.1–1.72, 
P=0.006, respectively.
The meta-analysis of all 3,920 patients identified a SNP, 
rs11212617 of the ATM gene, known to be involved in DNA 
repair and cell cycle control, which was associated with treat-
ment success (OR -1.35, 95% CI 1.22–1.49, P=2.9×10-9), 
and each copy of the minor C allele of rs11212617 was 
associated with 0.11% (P=6.6×10-7) lower absolute treat-
ment A1c.10
Further meta-analysis of 2,264 patients on metformin 
monotherapy showed that the OR for treatment success was 
1.42 (95% CI 1.26–1.62, P=4×10-8).10 In a subgroup analysis 
of 284 patients on metformin from the UKPDS study, 19% 
of patients who had two copies of the C allele at rs11212617 
had a 3.3-fold greater likelihood of achieving an A1c ,7%, 
which increased the variance in the response to metformin 
by 2.5% from 27.5% to 30% (P=0.007).10
In the South Danish Diabetes Study, 27 SNPs and one 
deletion of the metformin transporter genes were tested in 
371 T2DM patients.11 The mean trough steady-state plasma 
concentration of metformin was 576 ng/mL, with a wide, 
80-fold range (54–4,133 ng/mL), indicating that it was a 
true interindividual variability. Patients heterozygous for 
the minor alleles rs72552763, rs12208357, rs34130495, 
and rs34059508 in SLC22A1 showed a significantly lower 
trough concentration of metformin, which was additive 
with increasing number of reduced function SNPs.11 A large 
difference in the levels of OCT1/ OCT3 genetic variants 
expression in the liver, kidney, and intestines may contrib-
ute to reduced intestinal absorption, variations in hepatic 
uptake, increased renal clearance, and reduced clinical 
effect of metformin.11 The variant rs3413095 in SLC22A1 
was associated with a 1.1% (95% CI 0.4–1.8, P=0.003) 
higher A1c compared to patients who were homozygous 
for the wild-type allele at 6 months. The presence of SNP 
rs34399035 of SLC47A2 in the heterozygous patients was 
thought to be associated with a long-term decrease in A1c 
1.1% (95% CI -0.1–2.2, P=0.06) compared with the wild-
type patients over 24 months.11
In 52 men with heart disease and metabolic syndrome or 
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exhibited a high therapeutic efficacy in patients who carried 
the Pro/Pro allele of the SNP Pro12Ala polymorphism of the 
PPARγ2 gene.12 These patients had significant reduction in 
weight, waist circumference, body mass index (BMI), and 
concentrations of total cholesterol and inflammatory factors 
like interleukin (IL)-1beta, IL-6, IL-8, and tumor necrosis 
factor-alpha.12
Sulphonylureas and meglitinides
Sulphonylureas (SU), one of the oldest oral agents used in 
T2DM, stimulates insulin secretion by inhibiting adenosine 
triphosphate (ATP)-sensitive potassium (KATP) channels.3 
Meglitinides act similarly but produce a less sustained rise 
in insulin secretion. SU have been well studied as they have 
implication in the treatment of monogenic diabetes.13 Gene 
mutations in the inwardly rectifying potassium channel 
(KCNJ11) and the ABCC8 modify the insulin response to 
SU therapy and may be responsible for the interindividual 
variability and adverse effects seen in T2DM patients.13
SU given to 101 T2DM patients uncontrolled on met-
formin monotherapy showed a higher decrease in A1c at 
6 months in K allele carriers of the KCNJ11 gene variant 
E23K when compared with EE homozygotes (1.04%±0.10% 
versus 0.79%±0.12%, P=0.036, respectively).14 K allele 
carriers of the E23K variant of the KCNJ11 gene15 and 
the Gly972Arg polymorphism of the insulin receptor sub-
strate 1 (IRS1)16 were more susceptible to secondary failure, 
defined as requiring insulin secondary to plasma glucose 
levels .300 mg/dL. In 525 T2DM patients, the frequency of 
carriers of the K allele of the SNP E23K of the KCNJ11 gene 
(E23K heterozygotes and K23K homozygotes) was higher 
(66.8%) in patients who failed SU therapy compared to 58% 
in patients who did not fail, and they had a significant relative 
risk of secondary failure of 1.45 (95% CI 1.01–2.09, P=0.04) 
compared with E23E homozygotes, which did not change, 
even after adjustment for clinical factors like age, sex, fasting 
plasma glucose (FPG), A1c, BMI, age at diagnosis, and dura-
tion of diabetes (OR 1.69, 95% CI 1.02–2.78, P=0.04).15 In 
477 Caucasian T2DM patients, the Gly972Arg polymorphism 
of the IRS1 gene was found in 8.7% of well-controlled T2DM 
patients on oral therapy versus 16.7% in patients with second-
ary failure to SU.16 This SNP was associated with relative risk 
of 2.7 (1.02–7.28, P=0.045) to 2.0 (1.38 –3.86, P=0.038) of 
secondary SU failure, which persisted even after adjustment 
for various clinical factors like age, sex, FPG, A1c, BMI, age 
at diagnosis, and duration of diabetes.16
KATP channels containing the K23/A1369 haplotype 
of the genes KCNJ11 and ABCC8 were significantly less 
sensitive to inhibition by tolbutamide, chlorpropamide, and 
glimepiride and more sensitive to inhibition by mitiglinide 
and gliclazide when compared to the SNP E23/S1369.17 
Nateglinide, glipizide, and glibenclamide showed similar 
inhibitory profiles in KATP channels containing either 
haplotype.17
Carriers of the T-allele (TT + TG) of the SNP rs163184 
(T.G) of another diabetes susceptibility gene expressed 
in β-cells (KCNQ1) achieved significantly lower FPG 
(6.95 mmol/L [125 mg/dL]) 6 months after therapy with 
SU in 87 T2DM patients uncontrolled on metformin mono-
therapy when compared to the GG genotype (7.50 mmol/L 
[135 mg/dL]).18 In 367 Chinese T2DM patients on repaglin-
ide, those with the rs2237892 risk C allele of the gene KCNQ1 
had a significantly lower fasting insulin (FI) and homeostasis 
model assessment of insulin resistance (HOMA-IR) levels 
than carriers of the T allele.19 Patients with the rs2237895 risk 
C allele had significantly higher FPG, postprandial plasma 
glucose (PPPG), and HOMA-IR values when compared to 
patients with the A allele. Thus, response to repaglinide treat-
ment may be better in patients with the rs2237892 T allele 
and rs2237895 C allele compared to those with the rs2237892 
CC and rs2237895 AA genotypes.19 Similarly, in 209 newly 
diagnosed T2DM Chinese patients given repaglinide for 
48 weeks, the presence of the rs2237892 TT homozygotes 
showed a significantly lower PPPG (P=0.03) when compared 
to the C allele carriers.20
To assess which other genetic polymorphisms are associ-
ated with metabolism of repaglinide, 368 Chinese patients 
with T2DM were compared to 132 healthy controls.21 The 
frequency of allele T45 of the gene NeuroD1/BETA2 was 
significantly higher in T2DM patients (13.45%) than in the 
controls (6.8%, P,0.01, OR =2.342 [95% CI 1.365–4.019], 
P=0.002). Patients with the A45T polymorphism had higher 
FI and postprandial serum insulin (PPI) compared to the sub-
jects with the T allele. These T allele subjects, after repaglin-
ide therapy, were shown to have attenuated FPG and PPPG 
  levels.21 In R121W R allele carriers of the PAX4 gene, the RR 
genotype had higher PPI levels and better lowering of both 
FPG and PPPG levels when compared to the R/W genotypes 
(-6.53±6.52 versus -2.95±1.17 mmol l (-1), P,0.05).21 In 
443 Chinese T2DM patients on repaglinide for 8 weeks and 
229 healthy volunteers, rs13266634 risk C allele of the gene 
SLC30A8 was found in a significantly higher frequency in 
T2DM patients than in controls (P,0.05).22 The rs13266634 
CT + TT genotypes had higher FI and PPI levels compared 
with CC genotype carriers. T2DM patients with rs16889462 
GA genotype of the gene SLC30A8 showed a higher reduction Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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in FPG, PPPG, and A1c with repaglinide therapy compared 
with subjects with the GG genotype.22
Thiazolidinediones
Thiazolidinediones act as insulin-sensitizers through acti-
vation of the transcription factor peroxisome proliferator-
activated receptor-gamma 2 (PPARγ2), which plays a pivotal 
role in adipocyte differentiation and expression of adipocyte-
specific genes.3 The efficacy of rosiglitazone (4 mg/day for 
12 weeks) in relation to PPARγ2 genetic variations was 
studied in 198 T2DM patients.23 The presence of the Ala12 
allele lead to significantly lower FPG and A1c (2.8 mmol/L 
[50.6 mg/dL] and 1.41%) when compared to those without 
the allele (1.3 mmol/L [24.3 mg/dL] and 0.57% reduction, 
P=0.26 and P=0.01, respectively).23 In addition, there was 
a significant difference in the response rate to rosiglitazone 
therapy between the Pro12Pro and the Pro12Ala variant 
groups (43.72% versus 86.67%).23
In 250 Chinese T2DM patients on pioglitazone (30 mg/day 
for 24 weeks), the Ala12Ala and Pro12Ala genotypes and Ala 
allele of the PPARγ gene were significantly more frequent 
in pioglitazone responders than in nonresponders (26.0% 
versus 13.5%, P=0.025 and 15.6% versus 7.3%, P=0.008).24 
The decrease in FPG (2.8 mmol/L [50.4 mg/dL] versus 2.4 
mmol/L [43.3 mg/dL], P,0.001) and A1c (0.57% versus 
0.35%, P=0.004) levels was significantly greater in subjects 
with the Pro12Ala and Ala12Ala carriers than in Pro12Pro 
carriers. On further analysis, only the PPARγ Pro12Ala 
polymorphism was found to be associated with the response 
to pioglitazone.24 This finding was not replicated in 113 
T2DM patients from Germany, where both Pro12Ala and 
the Pro12Pro variants were not associated with response 
to pioglitazone.25 In 101 Iranian T2DM patients, even 
though the Pro12Ala genotype showed a better therapeutic 
response compared to the Pro12Pro genotype, the difference 
between groups was not statistical significance.26 However, 
a recent meta-analysis showed that patients with PPARγ gene 
Pro12Ala polymorphism had a more favorable change in 
FPG with pioglitazone (P=0.018) when compared with the 
Pro12Pro genotype.27
In 197 Chinese Han T2DM patients of whom 67 patients 
were given pioglitazone (30 mg/day for 12 weeks), those 
patients with PPARγ2 gene polymorphism rs1801282 CG 
showed significantly higher levels of PPPG and serum 
  triglyceride compared with those with rs1801282 CC 
  genotype.28 In patients with protein tyrosine phosphatase 
receptor type D gene polymorphism rs17584499, the CC 
genotype had better PPPG levels compared with CT + TT 
genotypes.28 In 241 Chinese patients with T2DM of whom 
41 patients were given rosiglitazone (4 mg daily for 12 weeks), 
the presence of the SNPs Thr394Thr and Gly482Ser of the 
PPARγ coactivator-1 gene increased the therapeutic efficacy 
of rosiglitazone when compared to controls.29
Other genes related to leptin, resistin, and adiponectin 
have been studied. In 245 Chinese patients with T2DM and 
122 healthy volunteers, the frequency of the SNPs of the 
leptin gene G-2548A and TNF-alpha gene G-308A were 
the same.30 At baseline in 42 T2DM patients on rosiglitazone 
(4 mg daily for 8 weeks), those with the G allele of leptin 
G-2548A had a higher FPG levels compared to the AA geno-
types (P,0.05). The effect on FI and PPI were enhanced 
with rosiglitazone therapy in patients with AA genotype of 
leptin G-2548A when compared with GG + GA genotype. 
There was an attenuated effect on FI in patients with GA + 
AA genotype of TNF-alpha G-308A compared with GG 
genotype (P,0.05).30
A prospective study of 121 T2DM patients and retrospec-
tive data from 63 T2DM patients treated with pioglitazone 
for 12 weeks revealed that the G/G but not C/G genotype 
of the resistin gene promoter SNP at -420, rs1862513 had 
lower FPG (P=0.020) and better HOMA-IR (P=0.012) 
when compared to C/C genotype.31 Patients on rosiglitazone 
monotherapy (4 mg daily for 12 weeks) with SNP rs11377CC 
homozygote genotype and 45TG + GG heterozygote geno-
type of the adiponectin common polymorphisms 45T/G 
and -11377C/G had a better response in FPG, PPPG, 
  HOMA-IR, and serum adiponectin levels (P=0.000) com-
pared with 11377CG + GG heterozygote and 45TT homozy-
gote   genotypes.32 This was contradicted in another study 
of Chinese T2DM patients, where the 11377CG genotype 
had a better response in FPG and A1c when compared to the 
11377 CC polymorphism.33 The presence of the two SNPs, 
45T/G and 795G/A, in 101 Iranian patients with T2DM on 
pioglitazone for 12 weeks were not significantly associated 
with the response to pioglitazone.34
Genetic polymorphisms have been studied in other 
genes such as KCNQ1, UCP2, ADRB3, and LPL. The 
presence of rs2237897 allele of the KCNQ1 gene was 
associated with significant decrease in PPPG levels in 209 
Chinese T2DM patients given rosiglitazone for 48 weeks.20 
The frequency of the allele UCP2 -866G/A and ADRB3 
Trp64Arg genetic polymorphisms were the same in 472 
Chinese T2DM patients and 321 healthy volunteers.35 At 
baseline, the A allele carriers of UCP2 had significantly Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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lower PPI (61.5±34.3 versus 41.6±28.7 mU l (-1), P,0.01) 
and low-density lipoprotein-cholesterol (LDL-C) (3.4±1.1 
versus 2.7±1.1 mmol l (-1), P,0.05) compared with GG 
genotypes. After rosiglitazone 4 mg/day for 12 weeks there 
was improvement in PPI (-3.82±13.2 versus -42.1±30.7 mU 
l (-1), P,0.01) (9.45-51.31 versus 0.48–11.88 mU1[–1]) 
and greater attenuation of A1c (-1.85±1.62 versus 
  -0.61±0.80%, P,0.05) (0.14–1.37 versus 1.10–2.38%) 
compared with GG genotypes.35 Patients with ADRB3 
Trp64Arg when compared with ADRB3 Trp64Trp polymor-
phism had a better response in serum triglyceride, LDL-C, 
and adiponectin levels.35
In 113 T2DM patients on pioglitazone (30 mg/day for 
10 weeks), the presence of the SNP S447S genotype of the 
LPL gene had a significantly better response in FPG and 
A1c reduction, along with beneficial effects on lipid profile 
and blood pressure (BP) when compared to the S447X 
genotype.36
Glucagon-like peptide-1 analogs  
and dipeptidyl peptidase-4 
inhibitors incretins
Glucagon-like peptide-1 (GLP-1) analogs and dipeptidyl 
peptidase-4 (DPP-4) inhibitors, through their receptors on 
pancreatic α/β cells, stimulate the synthesis of insulin and 
suppress glucagon levels.37 The speculation is that any of the 
genetic variants which affect insulin synthesis/secretion may 
also affect the incretin response.38
The effect of 21 SNPs in GLP-1 receptor gene on insulin 
secretion was studied in 88 healthy young individuals, using 
a hyperglycemic clamp with GLP-1 being infused for the 
last 2 hours.37 Two of 21 SNPs (rs6923761 and rs3765467) 
were associated with altered response of the β-cell to the 
GLP-1 infusion, which may indicate that variations in the 
GLP-1 receptor may alter insulin secretion in response to 
exogenous GLP-1.37 However, this needs to be confirmed 
in T2DM patients with larger studies.
In 1,578 German subjects at high risk to develop diabe-
tes, the effect of KCNQ1 gene SNPs rs151290, rs2237892, 
rs2237895, and rs2237897 on insulin secretion in response 
to oral glucose tolerance test (OGTT), intravenous GTT 
(IVGTT), and to hyperglycemic clamp combined with 
GLP-1 and arginine administration was studied.38 Insulin 
secretion was lower in homozygous major allele carriers of 
SNPs, rs151290, rs2237892 , and rs2237897 while the β-cell 
function was improved in homozygous major allele carriers 
of rs2237895 (AA). However, during the hyperglycemic 
clamp combined with GLP-1 administration, there were no 
associations found between the KCNQ1 variants and glu-
cose,   GLP-1, and insulin secretion.38 In a subset of patients, 
there was a significant increase in OGTT-stimulated gastric 
inhibitory polypeptide (GIP) levels (P=0.019) with the SNP 
rs151290, even after adjustment for sex, age, and BMI. This 
may suggest that an altered incretin secretion after food 
intake provides a potential link between KCNQ1 gene vari-
ants and impaired β-cell function. This effect was not found 
with other variants, rs2237892, rs2237895, and rs2237897, 
and the authors concluded that this could be secondary to 
limited sample size or that these KCNQ1 variants regulate 
insulin secretion differently than rs151290.38
The transcription factor T-cell factor 7-like-2 (TCF7L2) 
is an essential factor for GLP-1 secretion from intestinal 
L-cells.39 The interaction between TCF7L2 and GLP-1/GIP 
receptors is important for β-cell function.40 When islet cells 
of patients with T2DM were treated with small interfering 
RNA to TCF7L2, the expression of the GLP-1 and GIP 
receptors were decreased, and there was impaired insulin 
secretion when stimulated by glucose and GLP-1/GIP.39 Of 
the five SNPs in the TCF7L2 gene which were genotyped 
in 1,110 nondiabetic German participants, there was a 
significant reduction in GLP-1-induced insulin secretion in 
carriers of rs7903146 and rs12255372 (P,0.02), which may 
be the result of a functional defect in GLP-1 signaling in 
β-cells rather than a reduction in GLP-1 secretion.40 In the 
presence of TCF7L2 gene variants (TT or TC at rs7903146) 
in eight subjects with high risk to develop T2DM, the β-cell 
response to OGTT was 50% lower (47±4 versus 95±15×109 
min (-1), P=0.01), and the incretin effect was also reduced 
by 30% (32%±4% versus 46%±4%, P=0.02) when com-
pared to ten matched subjects with wild-type genotype, 
while the response was similar in both groups to IVGTT.41 
The lower incretin effect occurred in spite of having the 
same level of GLP-1/GIP secretion to oral glucose in both 
groups, indicating that it may be secondary to the effect 
of TCF7L2 gene variants on the sensitivity of the β-cell 
to incretins.41
The WFS1 gene plays a significant role in the main-
tenance of homeostasis of the endoplasmic reticulum in 
pancreatic β-cells.42 In 1,578 subjects with high risk to 
develop T2DM, the SNP rs10010131 of the WFS1 gene was 
associated with reduced OGTT and GLP-1 infusion com-
bined with a hyperglycemic clamp-derived insulin secretion 
(P=0.03), with no difference between groups in IVGTT and 
hyperglycemic clamp.42Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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Gene variants of JAZF1, CDC123/CAMK1D, TSPAN8/
LGR5, THADA, ADAMTS9, NOTCH2/ADAMS30, DCD, 
VEGFA, BCL11A, HNF1B, WFS1, and MTNR1B were 
evaluated in a study with 180 subjects with normal glu-
cose tolerance and 156 subjects with impaired glucose 
tolerance.43 Certain gene variants in CDC123/CAMK1D, 
ADAMTS9, BCL11A, and MTNR1B affected various aspects 
of the insulin response to glucose (all P,6.9×10-3) while 
the THADA gene variant was associated with lower β-cell 
response to GLP-1 and arginine (both P,1.6×10-3). In 
carriers of MTNR1B, the trend seen toward an increased 
insulin response to GLP-1 (P=0.03), if confirmed, may be 
important clinically.43
The SNPs of the gene ABCB1, CGC/CGC, CGC/TTT, 
and TTT/TTT, did not influence sitagliptin pharmacokinet-
ics in ten healthy volunteers.44 Various SNPs of the DPP-4 
enzyme genes, g-234A/C, rs13015258, IVS8-128A/G, 
rs17848920, IVS8 + 46C/T, rs10930040, IVS11-143A/G, 
rs2302873, G645G, rs17848910, IVS22 + 4C/T, and 
rs2268891, studied to assess the efficacy of vildaglip-
tin, showed no significant associations, and the authors 
hypothesized that it could be secondary to a small sample 
size.45 DPP-4 gene variants could affect the efficacy of 
the DPP-4 inhibitors; however, there is no study currently 
proving that a patient with a specific variant in a specific 
gene shows a better response to a particular DPP-4 inhibi-
tor. The presence or absence of genetic variants regarding 
clinical response to incretin therapy, if predictive, could 
lead to cost savings.
Sodium glucose transport 2 
inhibitors
Sodium glucose transport 2 (SGLT2) inhibitors block the 
reabsorption of filtered glucose, leading to glucosuria, with 
improvements in glycemic control and weight loss. The 
SGLT2 gene (SLC5) has been mapped to chromosome 
16 p11.2,46 and up to 50 different mutations of this gene 
have been reported and lead to familial renal glucosuria.47,48 
Genotyping for four common genetic variations in the SLC5 
gene in 1,013 nondiabetic German subjects showed that the 
SNP rs9934336 G allele was found with increased 30-minute 
plasma glucose, 120-minute insulin concentrations, and 
120-minute area under the curve glucose during OGTT.49 
In 2,590 nondiabetic subjects from Berlin, there was a 
nominal association with the 120-minute insulin concentra-
tions, suggesting a possible role in the regulation of glucose 
homeostasis for SLC5 gene variants.49 So far, there have 
been no definitive studies of patients with T2DM regarding 
the genetic variants and SNPs associated with response to 
the SGLT2 inhibitors.
Canagliflozin: role of clinical profiling –   
efficacy and adverse events data
effect on glycemic parameters and weight
In multiple Phase III studies lasting from 26–52 weeks, a 
total of 4,978 patients who were either treatment-naïve or 
on mono/dual oral agents were randomized to canagliflozin 
100 and 300 mg daily versus placebo, glimiperide, and 
sitagliptin.50–55 The placebo-corrected reduction in A1c, FPG, 
and PPPG with canagliflozin 100 and 300 mg were significant. 
The A1c reductions with canagliflozin 100  and 300 mg ranged 
from 0.63–0.91% versus 0.97–1.16%, respectively.50–52 The 
FBG and PPBG reductions with cangliflozin 100 mg and   
300 mg ranged from 1.2–2.0 mmol/L (21.6–36 mg/dL) 
and 2.7 mmol/L (48.6 mg/dL) versus 1.92–2.4 mmol/L 
(34.5–43.2 mg/dL) and 3.6 mmol/L (63.8 mg/dL), 
respectively.50–52  Weight loss of 1.4–3.0 kg was found with 
canagliflozin 100 mg and 2.0–3.8 kg with canagliflozin 
300 mg. The decrease in A1c was similar between treatment-
naïve patients and those already on oral antihyperglycemic 
therapy.50–52
The mean A1c and FPG reduction with the canagli-
flozin 100 mg dose was noninferior to glimiperide, 0.82% 
and 0.81% and 1.4 and 1.0 mmol/L (25.2 and 18 mg/dL), 
respectively, while the canagliflozin 300 mg group showed 
superiority (0.93% and 1.5 mmol/L [27 mg/dL] reduction, 
respectively).53 The A1c reduction was sustained for 52 weeks 
in the canagliflozin groups while it started to rise after week 
18 in the glimiperide group. A mean weight reduction of 
4.2–4.7 kg was noted with canagliflozin compared to 1.0 
kg weight gain with glimiperide and was predominantly 
from fat mass as shown by a reduced percent total fat,53,56 
and accounted for two-thirds of the overall reduction, with 
slightly greater reductions in visceral fat.56 In the first study, 
where canagliflozin was compared to sitagliptin, there was a 
mean reduction in A1c and FPG in the canagliflozin (1.03% 
and 1.7 mmol/L [30.6 mg/dL]) versus sitagliptin (0.66% and 
0.3 mmol/L [5.4 mg/dL]).56 As with SU, there was an increase 
in A1c after week 12 in the sitagliptin group. A mean weight 
reduction of 2.5 kg was noted with canagliflozin compared 
to 0.3 kg weight gain with sitagliptin. The A1c goals of ,7% 
were reached in 47.6% with canagliflozin and 35.3% with 
sitagliptin.54 In the second study at week 52, the mean A1c 
reduction in canagliflozin 100 and 300 mg versus sitagliptin 
was comparable. Body weight decreased in canagliflozin 100 
and 300 mg (3.8%–4.2%) versus sitagliptin (1.3%).55Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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Data of 2,313 patients (1,868 ,65 years and 445 .65 years) 
from four Phase III studies showed that canagliflozin was 
efficacious in attaining a reduction in A1c, FPG, body weight, 
and systolic BP (SBP) in both groups when compared to 
placebo.57 However, data extraction from 15 clinical trials 
showed that in elderly T2DM patients, the A1c reduction 
was lower with canagliflozin when compared to younger 
population, while the reduction in SBP and weight was the 
same.58 In multiple Phase III studies, there was a significant 
increase in β-cell glucose sensitivity compared to placebo 
with canagliflozin, and it was noninferior to sitagliptin. This 
indicates that canagliflozin given for 26–52 weeks improved 
measures of β-cell function.59
effect on BP, pulse rate, and lipids
Canagliflozin showed a significant reduction in the placebo-
corrected mean SBP and diastolic BP in both dose groups, 
ranging from 1.62–10.7 mmHg and 1.6–7.0 mmHg, 
respectively.50–52 Canagliflozin showed a mean decrease in 
SBP (3.3–5.1 mmHg) versus an increase in the glimiperide 
(0.2 mmHg) and sitagliptin (0.9 mmHg) groups.53,54 Both 
canagliflozin groups showed a placebo-corrected significant 
increase in high-density lipoprotein-cholesterol (HDL-C) 
  levels (2.3%–10.7%),50,51 with triglycerides showing a 
minimal decrease (0.6%–12.8% ),50,51 and LDL-C showed an 
increase (1.9%–10.9%) in most studies.50–53 When canagli-
flozin 100 and 300 mg was compared to glimiperide, there 
was an increase in HDL-C of 7.9%, 9.0%, and 0.3%, respec-
tively, while the triglycerides showed a decrease of 3.7% in 
the canagliflozin 100 mg group compared to an increase of 
2.3% and 9.5% in the canagliflozin 300 mg and glimiperide 
groups, respectively.53 Similarly, HDL-C increased in the 
pooled canagliflozin groups (7.6%) compared to sitagliptin 
(0.6%) while triglycerides showed an increase in both cana-
gliflozin 300 mg (9.6%) and sitagliptin (11.9%).54 An increase 
in LDL-C was also seen in both canagliflozin 300 mg (11.7%) 
and sitagliptin (5.2%) groups.54
Adverse events
In Phase III studies, the incidence of adverse events (AEs) 
were similar between canagliflozin (50%–77%) versus pla-
cebo (53%–66%)51,52 versus glimiperide (68%) and sitagliptin 
(77.5%).53,54 Mild to moderate hypoglycemia episodes were 
higher in the pooled canagliflozin (0%–28%) versus placebo 
(2%),50–52 while it was lower (4.6%–5.6%) when compared to 
glimiperide (34.2%)53 and similar to sitagliptin.55 There were 
no severe hypoglycemic events reported in most studies.50,52–54 
Only small changes from baseline for serum creatinine, blood 
urea nitrogen, and serum urate were seen with canagliflozin 
relative to placebo.50,53 Small increases in hemoglobin were 
observed with canagliflozin (3.6% and 3.9%), whereas a 
slight decrease was observed with placebo (0.2%).50 Increased 
urinary frequency was low in the pooled canagliflozin groups 
(2.4%–5.3%) versus placebo (0%–0.5%).51–54 The incidence 
of serious AEs were similar in the pooled canagliflozin groups 
(2.1%–4.1%) versus placebo (1%–5.8%).50–52 Two deaths 
occurred during the treatment period, one each in the placebo 
and canagliflozin 100 mg group, and were deemed not to be 
drug related.50 The incidence of serious AEs when compared 
to glimiperide and sitagliptin were similar.53,54 There were 
no cardiovascular (CV) AEs reported in any study.50–54 AEs 
secondary to reduced intravascular volume such as postural 
dizziness/orthostatic hypotension were low (#3%).50,52
The incidence of overall AEs were the same in 
patients ,65 and $65 years of age.57 Serious AEs and 
AE-related discontinuations were higher in canagliflozin 
100 mg in the $65 year-old patient group. The incidence 
of genital mycotic infections and osmotic diuresis-related 
AEs were higher with canagliflozin in both age groups. 
Incidences of urinary tract infections (UTIs), renal-related 
AEs, AEs related to volume depletion, lipid parameters, 
and documented hypoglycemia episodes were similar in 
both groups, indicating that it was generally well tolerated 
in older T2DM patients.57
When T2DM patients on hydrochlorothiazide (HCTZ) 
were given canagliflozin, the change in 24-hour urine volume 
from baseline was -0.1 L with canagliflozin alone and 0.4 L 
with HCTZ alone and with canagliflozin + HCTZ.60 Most AEs 
were mild and higher with canagliflozin + HCTZ (69%) than 
with canagliflozin (47%) or HCTZ (50%) alone. There were 
minimal changes in serum electrolytes with canagliflozin + 
HCTZ compared with individual treatments. Canagliflozin 
coadministered with HCTZ was generally well tolerated.60 
Similarly, 36 T2DM patents on   angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers given 
canagliflozin showed a modest increase in urine volume 
initially which was attenuated at the end of the study.61 Mea-
sures of volume status which were modestly increased at the 
beginning remained elevated till the end.61
In pooled data from Phase III studies, the incidence of 
female and male genital mycotic infections in 2,313 and 
9,439 T2DM patients exposed to canagliflozin for 24 and 
68 weeks, respectively, were studied.62 In the first group, 
the incidence of genital mycotic infections was higher in 
females compared to males for both canagliflozin 100 (10.4% 
and 4.2%) and canagliflozin 300 mg (11.4% and 3.7%) versus Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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placebo (3.2% and 0.6%). In the second group, with 68 weeks 
exposure to canagliflozin, the incidence for canagliflozin 
100 and 300 mg versus placebo was females: 14.7%, 13.9%, 
3.1% versus males: 7.3%, 9.3%, 1.6%, respectively. Most 
were mild to moderate in intensity, occurred within the first 
4 months in females and first year in males, none were seri-
ous, few led to discontinuation, few patients had .1 event 
(females, 2.3%; males, 0.9%), were not dose dependent, and 
responded to standard treatments.62
Clinical profiling of canagliflozin
Based on the available data regarding the mechanism of cana-
gliflozin, its efficacy, and safety, the clinician may attempt to 
find the ideal T2DM patient for whom it may lead to certain 
benefits. As it acts independent of β-cell function or mass and 
insulin sensitivity, canagliflozin can be used at any stage of 
T2DM, any age, irrespective of the duration of diabetes and 
in combination with all other oral agents and insulin. Ideally, 
patients who need an A1c lowering from 0.5% to 1.17% may 
benefit from its use.50–54 It may be used as a second line agent 
in obese T2DM patients who need weight loss with fat mass 
reductions. In addition, the use of canagliflozin in patients on 
oral SU and/or insulin therapy may help to attenuate the weight 
gain associated with these agents. Additional benefits seen are 
BP reductions due to a diuretic effect, which appear to be safe, 
and may allow more T2DM patients to reach the goal BP with 
or without reduction in dose of antihypertensive medications.
It is unclear at this point if there is a clinical implication of 
increase in LDL-C levels associated with canagliflozin therapy on 
CV risk. At this time, it would be prudent to keep a close watch 
on the LDL-C levels and adjust statin therapy accordingly to 
maintain LDL goals and await the results of long-term CV studies 
like the Canagliflozin cardioVascular Assessment Study.
It may thus be appropriate at the present time to be cau-
tious about starting canagliflozin therapy in patients with a 
heavy preexisting CV burden. Even though UTIs and genital 
infections were mild to moderate in nature and the same 
in the ,65 and .65 year age groups, it may be prudent to 
avoid using it in patients with preexisting repeated episodes 
of candidiasis and/or UTIs, and the consequences of treat-
ment of these AEs may discourage the use of canagliflozin 
in the elderly patient. Increased urinary frequency in the 
less mobile elderly may lead to discomfort.
Discussion
The importance of genetic variants was shown in the 
monogenic forms of diabetes. The clinical implication 
of finding these single gene diabetes disorders is that the 
physicians can be certain that oral antihyperglycemic 
agents rather that insulin therapy can be used successfully 
to treat such patients. However, as monogenic diabetes 
is found only in a small percentage of patients, a similar 
discovery of genetic variants, which can guide and indi-
vidualize diabetes therapy in the more common T2DM that 
is multifactorial in origin, would be clinically significant. 
Genome-wide association studies have opened the door 
for patient profiling and research into genetic variants in 
multifactorial T2DM.
Another push for individualized management is that drug 
costs account for a large portion of the health expenditure 
in the US. The response to drugs is not always the same 
even in T2DM patients with similar phenotypes. At present, 
most physicians follow an algorithmic approach to T2DM 
  treatment. A prior knowledge of the drug response in a 
particular patient based on pharmacogenomics can lead to a 
more efficient use of the appropriate drugs. It would guide 
physicians in providing patients with the most effective treat-
ment strategy given their individual genetic background and 
avoid drug side effects in the process.
It appeared that oral antihyperglycemic therapy was more 
effective in the presence of certain genotypes. Clinically, it may 
be possible to tailor the type of medication used based on the 
presence or absence of the various genetic variants and thus 
identify patients who will have the highest benefit from these 
agents. It appears that most of the information on genetic vari-
ants and response to meglitinides and thiazolidinedione therapy 
comes from the Chinese and Japanese populations, which raises 
the question about its applicability to other ethnic groups.
A number of the genes are involved in drug metabolism in 
T2DM patients, and some of the information available in the 
literature needs further validation to ensure its   authenticity. 
There are several studies whose findings have not been 
replicated and, at present, cannot confirm association. The 
polymorphisms studied may only explain some of the vari-
ability in response to T2DM drug therapy. There are still 
unidentified factors including racial differences which appear 
to play a role in the interindividual variability seen in clinical 
practice. For example, the SNP CYP2C8*3 was found in 
higher frequency in Caucasians (10%–23%),63 followed by 
Hispanics, and is rare among people with African and Asian 
ancestry.63,64 The present studies have been done in certain 
ethnic groups, and further well-designed studies are needed 
to cover other ethnic groups found in the US and the rest 
of the world. Further studies to detect other genetic factors 
which may better explain the variability in drug treatment 
response is needed.Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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Advances in T2DM genetics may in the future improve 
disease prediction, prevention, and treatment. A barrier to the 
implementation of routine genetic testing may be the accep-
tance by physicians and patients. A recent survey of a sample 
of 304 nationally representative US primary care physicians 
and endocrinologists, 152 nondiabetic primary care patients, 
and 89 patients enrolled in a diabetes pharmacogenetics 
study was done to assess their reactions to genetic testing 
for T2DM.65 Both physicians (79%) and patients (80%) 
favored genetic testing for diabetes risk prediction. About 
71% of patients versus 23% of physicians indicated that a 
“high risk” result would be very likely to improve motiva-
tion to adopt preventive lifestyle changes. In addition, more 
patients favored genetic testing to guide therapy (78%) versus 
physicians (48%) and reported that genetic testing would 
make them “much more motivated” to adhere to medications 
(72%). Both physicians and patients have high expectations 
that genetic testing would improve patient motivation to 
control T2DM and can possibly motivate behavior change 
compared with standard risk information.65 Regarding cana-
gliflozin, until we have well-performed genetic studies, the 
decision to use canagliflozin or any other SGLT2 inhibitor 
should be individualized based on the health and presence 
of comorbid conditions on a case by case basis, especially in 
the older age patient groups. Adequate education should be 
provided to all patients prior to starting canagliflozin.
Conclusion
The potential exists for pharmacogenomics to promote 
efficacious, safe, and cost-effective, individualized diabetes 
management. However, pharmacogenomics is still in its 
early stages, and the idea of defining patients genetically 
to predict individual responses to drugs and obtain safe 
and effective T2DM management is promising in spite of 
existing barriers. Currently, clinical profiling of patients 
with T2DM and using an individualized approach with 
most drugs, including canagliflozin, based on comorbid 
conditions still remains the most accepted approach for the 
management of T2DM.
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